TY - JOUR
T1 - Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases
T2 - A DESTINY-Breast01 Subgroup Analysis
AU - Jerusalem, Guy
AU - Park, Yeon Hee
AU - Yamashita, Toshinari
AU - Hurvitz, Sara A.
AU - Modi, Shanu
AU - Andre, Fabrice
AU - Krop, Ian E.
AU - Farré, Xavier Gonzàlez
AU - You, Benoit
AU - Saura, Cristina
AU - Kim, Sung Bae
AU - Osborne, Cynthia R.
AU - Murthy, Rashmi K.
AU - Gianni, Lorenzo
AU - Takano, Toshimi
AU - Liu, Yali
AU - Cathcart, Jillian
AU - Lee, Caleb
AU - Perrin, Christophe
N1 - Publisher Copyright:
© 2022 The Authors;.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We present a subgroup of 24 patients with a history of treated brain metastases (BM), a population with limited treatment options. In patients with BMs, the confirmed objective response rate (cORR) was 58.3% [95% confidence interval (CI), 36.6%–77.9%], and the median progression-free survival (mPFS) was 18.1 months (95% CI, 6.7–18.1 months). In patients without BMs (n = 160), cORR was 61.3% and mPFS was 16.4 months. Eight patients (47.1%) experienced a best overall intracranial response of partial response or complete response. Seven patients (41.2%) had a best percentage change in brain lesion diameter from baseline consistent with stable disease. Two patients (8.3%) with BMs and two (1.3%) without BMs experienced progression in the brain. The safety profile of T-DXd was consistent with previous studies. The durable clinical activity of T-DXd in this population warrants further investigation.
AB - DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We present a subgroup of 24 patients with a history of treated brain metastases (BM), a population with limited treatment options. In patients with BMs, the confirmed objective response rate (cORR) was 58.3% [95% confidence interval (CI), 36.6%–77.9%], and the median progression-free survival (mPFS) was 18.1 months (95% CI, 6.7–18.1 months). In patients without BMs (n = 160), cORR was 61.3% and mPFS was 16.4 months. Eight patients (47.1%) experienced a best overall intracranial response of partial response or complete response. Seven patients (41.2%) had a best percentage change in brain lesion diameter from baseline consistent with stable disease. Two patients (8.3%) with BMs and two (1.3%) without BMs experienced progression in the brain. The safety profile of T-DXd was consistent with previous studies. The durable clinical activity of T-DXd in this population warrants further investigation.
UR - http://www.scopus.com/inward/record.url?scp=85143202664&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-22-0837
DO - 10.1158/2159-8290.CD-22-0837
M3 - Article
C2 - 36255231
AN - SCOPUS:85143202664
SN - 2159-8274
VL - 12
SP - 2754
EP - 2762
JO - Cancer Discovery
JF - Cancer Discovery
IS - 12
ER -